vs

Side-by-side financial comparison of Chatham Lodging Trust (CLDT) and 4D Molecular Therapeutics, Inc. (FDMT). Click either name above to swap in a different company.

4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $67.7M, roughly 1.3× Chatham Lodging Trust). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 6.8%, a 16.0% gap on every dollar of revenue. On growth, 4D Molecular Therapeutics, Inc. posted the faster year-over-year revenue change (8508900.0% vs -9.8%). Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs -0.5%).

Chatham Lodging Trust is a publicly traded real estate investment trust that invests in, owns, and operates upscale extended-stay and select-service premium hotel properties primarily across high-demand urban and suburban markets in the United States. Its portfolio targets assets with strong occupancy rates and steady cash flow from business and leisure traveler segments.

4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.

CLDT vs FDMT — Head-to-Head

Bigger by revenue
FDMT
FDMT
1.3× larger
FDMT
$85.1M
$67.7M
CLDT
Growing faster (revenue YoY)
FDMT
FDMT
+8508909.8% gap
FDMT
8508900.0%
-9.8%
CLDT
Higher net margin
FDMT
FDMT
16.0% more per $
FDMT
22.8%
6.8%
CLDT
Faster 2-yr revenue CAGR
FDMT
FDMT
Annualised
FDMT
5412.6%
-0.5%
CLDT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLDT
CLDT
FDMT
FDMT
Revenue
$67.7M
$85.1M
Net Profit
$4.6M
$19.4M
Gross Margin
Operating Margin
15.9%
17.3%
Net Margin
6.8%
22.8%
Revenue YoY
-9.8%
8508900.0%
Net Profit YoY
369.9%
139.1%
EPS (diluted)
$0.05
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLDT
CLDT
FDMT
FDMT
Q4 25
$67.7M
$85.1M
Q3 25
$78.4M
$90.0K
Q2 25
$80.3M
$15.0K
Q1 25
$68.6M
$14.0K
Q4 24
$75.1M
$1.0K
Q3 24
$87.2M
$3.0K
Q2 24
$86.5M
$5.0K
Q1 24
$68.4M
$28.0K
Net Profit
CLDT
CLDT
FDMT
FDMT
Q4 25
$4.6M
$19.4M
Q3 25
$3.5M
$-56.9M
Q2 25
$5.4M
$-54.7M
Q1 25
$1.5M
$-48.0M
Q4 24
$-1.7M
Q3 24
$4.3M
$-43.8M
Q2 24
$6.8M
$-35.0M
Q1 24
$-5.2M
$-32.4M
Gross Margin
CLDT
CLDT
FDMT
FDMT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
40.7%
Q3 24
44.7%
Q2 24
46.1%
Q1 24
38.9%
Operating Margin
CLDT
CLDT
FDMT
FDMT
Q4 25
15.9%
17.3%
Q3 25
12.7%
-67983.3%
Q2 25
14.8%
-396373.3%
Q1 25
12.1%
-383007.1%
Q4 24
7.5%
Q3 24
14.3%
-1704400.0%
Q2 24
16.3%
-849120.0%
Q1 24
1.4%
-136200.0%
Net Margin
CLDT
CLDT
FDMT
FDMT
Q4 25
6.8%
22.8%
Q3 25
4.5%
-63195.6%
Q2 25
6.7%
-364386.7%
Q1 25
2.2%
-342657.1%
Q4 24
-2.3%
Q3 24
4.9%
-1461433.3%
Q2 24
7.9%
-699060.0%
Q1 24
-7.6%
-115717.9%
EPS (diluted)
CLDT
CLDT
FDMT
FDMT
Q4 25
$0.05
$0.43
Q3 25
$0.03
$-1.01
Q2 25
$0.07
$-0.98
Q1 25
$-0.01
$-0.86
Q4 24
$-0.08
Q3 24
$0.05
$-0.79
Q2 24
$0.10
$-0.63
Q1 24
$-0.15
$-0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLDT
CLDT
FDMT
FDMT
Cash + ST InvestmentsLiquidity on hand
$24.4M
$402.7M
Total DebtLower is stronger
$338.9M
Stockholders' EquityBook value
$740.8M
$505.7M
Total Assets
$1.2B
$566.7M
Debt / EquityLower = less leverage
0.46×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLDT
CLDT
FDMT
FDMT
Q4 25
$24.4M
$402.7M
Q3 25
$13.2M
$305.1M
Q2 25
$17.2M
$293.2M
Q1 25
$18.6M
$321.4M
Q4 24
$20.2M
$424.9M
Q3 24
$19.3M
$501.9M
Q2 24
$10.6M
$541.9M
Q1 24
$72.3M
$525.9M
Total Debt
CLDT
CLDT
FDMT
FDMT
Q4 25
$338.9M
Q3 25
$338.8M
Q2 25
$351.2M
Q1 25
$381.1M
Q4 24
$406.9M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CLDT
CLDT
FDMT
FDMT
Q4 25
$740.8M
$505.7M
Q3 25
$749.4M
$369.0M
Q2 25
$754.1M
$420.9M
Q1 25
$754.7M
$469.7M
Q4 24
$758.2M
$510.6M
Q3 24
$765.3M
$552.9M
Q2 24
$766.5M
$588.3M
Q1 24
$765.0M
$600.6M
Total Assets
CLDT
CLDT
FDMT
FDMT
Q4 25
$1.2B
$566.7M
Q3 25
$1.2B
$424.0M
Q2 25
$1.2B
$473.6M
Q1 25
$1.2B
$515.7M
Q4 24
$1.3B
$560.4M
Q3 24
$1.3B
$604.0M
Q2 24
$1.3B
$620.1M
Q1 24
$1.3B
$629.9M
Debt / Equity
CLDT
CLDT
FDMT
FDMT
Q4 25
0.46×
Q3 25
0.45×
Q2 25
0.47×
Q1 25
0.50×
Q4 24
0.54×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLDT
CLDT
FDMT
FDMT
Operating Cash FlowLast quarter
$64.1M
$28.6M
Free Cash FlowOCF − Capex
$28.5M
FCF MarginFCF / Revenue
33.5%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
13.90×
1.47×
TTM Free Cash FlowTrailing 4 quarters
$-109.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLDT
CLDT
FDMT
FDMT
Q4 25
$64.1M
$28.6M
Q3 25
$25.6M
$-46.5M
Q2 25
$22.1M
$-43.4M
Q1 25
$4.2M
$-47.8M
Q4 24
$73.8M
$-134.6M
Q3 24
$28.8M
$-29.4M
Q2 24
$25.2M
$-30.2M
Q1 24
$6.9M
$-29.1M
Free Cash Flow
CLDT
CLDT
FDMT
FDMT
Q4 25
$28.5M
Q3 25
$-46.6M
Q2 25
$-43.4M
Q1 25
$-48.4M
Q4 24
$-138.4M
Q3 24
$-31.2M
Q2 24
$-30.6M
Q1 24
$-29.8M
FCF Margin
CLDT
CLDT
FDMT
FDMT
Q4 25
33.5%
Q3 25
-51765.6%
Q2 25
-289620.0%
Q1 25
-345635.7%
Q4 24
-13837100.0%
Q3 24
-1038966.7%
Q2 24
-611840.0%
Q1 24
-106421.4%
Capex Intensity
CLDT
CLDT
FDMT
FDMT
Q4 25
0.1%
Q3 25
101.1%
Q2 25
440.0%
Q1 25
4507.1%
Q4 24
378600.0%
Q3 24
59266.7%
Q2 24
6980.0%
Q1 24
2535.7%
Cash Conversion
CLDT
CLDT
FDMT
FDMT
Q4 25
13.90×
1.47×
Q3 25
7.24×
Q2 25
4.10×
Q1 25
2.73×
Q4 24
Q3 24
6.78×
Q2 24
3.68×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLDT
CLDT

Occupancy$61.5M91%
Hotel Other$4.2M6%
Food And Beverage$1.8M3%
Hotel$1.1M2%

FDMT
FDMT

Segment breakdown not available.

Related Comparisons